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Abstract
Background: Loss of heterozygosity (LOH) is a common genetic event in cancer development, and is known to be
involved in the somatic loss of wild-type alleles in many inherited cancer syndromes. The wider involvement of
LOH in cancer is assumed to relate to unmasking a somatically mutated tumour suppressor gene through loss of
the wild type allele.
Methods: We analysed 86 ovarian carcinomas for mutations in 980 genes selected on the basis of their location in
common regions of LOH.
Results: We identified 36 significantly mutated genes, but these could only partly account for the quanta of LOH in
the samples. Using our own and TCGA data we then evaluated five possible models to explain the selection for
non-random accumulation of LOH in ovarian cancer genomes: 1. Classic two-hit hypothesis: high frequency
biallelic genetic inactivation of tumour suppressor genes. 2. Epigenetic two-hit hypothesis: biallelic inactivation
through methylation and LOH. 3. Multiple alternate-gene biallelic inactivation: low frequency gene disruption. 4.
Haplo-insufficiency: Single copy gene disruption. 5. Modified two-hit hypothesis: reduction to homozygosity of
low penetrance germline predisposition alleles. We determined that while high-frequency biallelic gene
inactivation under model 1 is rare, regions of LOH (particularly copy-number neutral LOH) are enriched for
deleterious mutations and increased promoter methylation, while copy-number loss LOH regions are likely to
contain under-expressed genes suggestive of haploinsufficiency. Reduction to homozygosity of cancer
predisposition SNPs may also play a minor role.
Conclusion: It is likely that selection for regions of LOH depends on its effect on multiple genes. Selection for
copy number neutral LOH may better fit the classic two-hit model whereas selection for copy number loss may
be attributed to its effect on multi-gene haploinsufficiency. LOH mapping alone is unlikely to be successful in
identifying novel tumour suppressor genes; a combined approach may be more effective.
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Background
Cancer cells undergo multiple genetic and epigenetic
hits in the development of tumorigenic phenotypes, in-
cluding somatic point mutations, increases in copy num-
ber, gene deletions, gene rearrangements, translocations
and promoter hypermethylation [1]. These random
events are selected for due to their effect on oncogenes,
where the aberration activates the gene to promote
tumorigenesis (e.g. KRAS, MYC), and on tumour suppres-
sor genes (TSG), where the genetic or epigenetic aberra-
tions is inactivating (e.g. TP53, PTEN), since the normal
function of these genes is to restrict tumorigenic potential.
Loss of heterozygosity (LOH) is a common genetic
event in many cancer types, so-called because of the
early observations of a change in polymorphic markers
from a heterozygous state in the germline to an appar-
ently homozygous state in the tumour DNA [2]. LOH is
a general term that encompasses both LOH with copy
number losses (CNL-LOH) and copy number neutral
LOH (CNN-LOH). In CNL-LOH all or part of a
chromosome is deleted. CNN-LOH originates either
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through a homologous recombination event (“gene con-
version”), or because the retained chromosome was du-
plicated either before or after the LOH event. LOH is
strongly associated with loss of the wild-type allele in in-
dividuals with an inherited cancer predisposition syn-
drome and carry a germline mutation in genes such as
RB1 in retinoblastoma or BRCA1 in breast and ovarian
cancer [2, 3]. This “second hit” hypothesis was initially
proposed by Knudson based on his observations of the
incidence of familial retinoblastoma [4] and has been
widely accepted as a mechanism for the complete inacti-
vation of tumour suppressor genes, both in a germline
context and the sporadic cancer context where the first
hit is a somatic event, such as mutation of TP53. As a
consequence, mapping of common regions of minimal
LOH has historically been a popular strategy to pursue
the identification of novel TSGs without the need for
segregation data from large cancer families. However,
such analyses have been generally been unsuccessful
leading to speculation that the approach is technically
and conceptually flawed [5], and even to whether there
is any selective advantage to LOH events. Nonetheless,
we previously used SNP mapping arrays to analyse LOH
in ovarian carcinomas of diverse histological subtypes,
with the rationale that the newer methodology would at
least overcome some of the previous technical issues
with LOH analyses [6]. We mapped a number of min-
imal regions of LOH containing tumour suppressor gene
candidates, including regions of homozygous deletion
encompassing genes such as MAP2K4 [7]. Advances in
massively parallel sequencing has enabled the current
study where we report targeted sequencing of 980 candi-
date tumour suppressor genes in 86 ovarian carcinomas,
most of which have matched SNP array data enabling
the assessment of the importance of LOH in the selec-
tion for somatic mutations in ovarian cancer. We evalu-
ated a number of different histological subtypes, since
these have different etiologies and causative genes.
Methods
Ethics statement
Accrual and use of patient material for this study was
approved by the following Human Research Ethics
Committees: Peter MacCallum Cancer Centre Human
Research Ethics Committee, Southampton Hospital
Human Research Ethics Committee, University of
Melbourne Human Research Ethics Committee, Queens-
land Institute of Medical Research Human Research
Ethics Committee, Westmead Hospital Human Research
Ethics Committee. All individuals gave written informed
consent for the use of their tissue in research. This project
was approved by the Peter MacCallum Cancer Centre
Human Research Ethics Committee (Approval # 09/29).
Ovarian tumour cohort
A tumour cohort (n = 86) comprising a variety of histo-
logical subtypes including serous (n = 45), endometrioid
(n = 28), mucinous (n = 7) and clear cell (n = 6) were ob-
tained through the Australia Ovarian Cancer Study, the
Peter MacCallum Cancer Centre Tissue Bank, or from
patients presenting to hospitals in the south of England
[8]. The majority of tumour DNA samples were needle
microdissected to ensure greater than 70 % cancer epi-
thelial cell component; other samples were processed
from tissue where the reference haematoxylin and eosin
stained section showed >70 % tumour epithelial cells.
Matching peripheral blood samples were also col-
lected from patients at time of tumour collection
and used as a source of germline DNA for somatic
mutation detection. Details of the cohort are listed
in Additional file 1: Table S1.
Library preparation, target enrichment and sequencing
Library preparation was performed as previously described
[9] following the Illumina genomic DNA library prepar-
ation protocol (Illumina, San Diego, CA) using an input of
200 ng of tumour or matched normal lymphocyte DNA.
Seven custom multiplexing adapters compatible with Illu-
mina single-end sequencing were used and indexed DNA
samples were pooled equally prior to PCR enrichment. A
boutique exon capture (SureSelect, Agilent Technologies,
Santa Clara, CA) was used to enrich for coding exons of
candidate tumour suppressor genes (n = 980, Additional
file 1: Tables S2 and S3) and known cancer genes (TP53,
BRCA1, BRCA2) according to the recommended protocol.
Capture probes were designed using default parameters in
eArray (Agilent Technologies).
Sequencing of target-enriched DNA libraries were per-
formed using an Illumina GAIIx, generating 75 bp
single-end sequence reads. Image analysis and base call-
ing was performed using the Genome Analyser Pipeline
v1.5-1.7. Sequence reads were aligned to the human ref-
erence genome (GRCh37/hg19 assembly) using BWA
[10] and any remaining unmapped reads aligned with
Novoalign [11]. The mean coverage for bases within tar-
get regions was 70-fold and 92 % had at least 10-fold
coverage. This was followed by local realignment with
GATK [12]. Point mutations and insertions/deletions
(indels) were identified using GATK and Dindel [13] re-
spectively, and annotated according to Ensembl release
56. Sequence variants were called as somatic alterations
only when (i) the variant was not called in the matched
normal sample or identified as a germline alteration in
another tumour/normal pair (ii) the variant was not seen
in > =2 independent reads in the matched normal sample
following manual inspection of sequence reads using the
Integrated Genomics Viewer [14] (iii) the variant was
identified in bi-directional sequence reads.
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A selection of variants that met the above criteria for a
somatic mutation (n = 202) were subjected to validation
by conventional PCR amplification and bidirectional ca-
pillary electrophoresis on the ABI3130 Genetic Analyser
using BigDye Terminator v3.1 sequencing chemistry
(Applied Biosystems, Foster City, CA).
SNP arrays and loss of heterozygosity
Affymetrix SNP Mapping array data was obtained for
the 86 sequenced cases, 54 by SNP6 arrays (GSE19539,
[15]), 26 by 500 K arrays (previously published in [6]),
and six previously unreported low-grade endometrioid
cases. Affymetrix SNP6 CEL files, HM27 methylation
array data (level 3), Agilent expression array data (level
3) and somatic mutation data from 266 tumors gener-
ated by The Cancer Genome Atlas (TCGA) were down-
loaded from the TCGA Data Portal. LOH was detected
as described previously in Partek Genomics Suite (Partek,
St Louis, MO), using allele-specific copy number that
compared the tumour genotype to the matching normal
genotype, and evaluated the copy number at heterozygous
alleles [6]. The “min” allele had to have a value of <0.5
copies to be called LOH, thus excluding regions of allelic
imbalance where at least one copy of both alleles was
present. The results published here are in whole or part
based upon data generated by The Cancer Genome Atlas
pilot project established by the NCI and NHGRI. Informa-
tion about TCGA and the investigators and institutions
who constitute the TCGA research network can be found
at http://cancergenome.nih.gov.
Results and discussion
A candidate TSG screen in ovarian cancer – selection of
genes from LOH regions
Candidate ovarian tumour suppressor genes (n = 980)
were selected for analysis on the basis of their location
in frequent regions of LOH or deletion (Additional file
1: Tables S2 and S3) from our previously published SNP
array analysis of 122 primary ovarian carcinomas of vari-
ous histologies [6]. The regions, located on 20 different
chromosome arms, met the following three criteria.
Firstly, minimal overlapping regions of LOH were in-
cluded if they were detected in greater than 35 % of all
ovarian carcinomas analysed, or secondly, in >35 % of sub-
type specific minimal overlapping regions of LOH (4 of 9
clear cell carcinomas, 5 of 12 low-grade endometrioid car-
cinomas (grades 1 and 2), 6 of 16 mucinous carcinomas
and 23 of 64 high-grade serous/endometrioid carcinomas
(grades 2 and 3 for the serous subtype, grade 3 for endo-
metrioid carcinomas)). Finally, all homozygous deletions
within frequent regions of LOH along with the overlap-
ping portion of all recurrent homozygous deletions were
included. This gene list included genes with well estab-
lished roles in cancer such as CDKN2A and PTEN, but for
the purposes of this analysis they were included in the
“candidate” LOH genes. In addition, the known ovarian
cancer genes TP53, BRCA1 and BRCA2 were included
despite lying outside the minimal regions of LOH.
A candidate TSG screen in ovarian cancer – correlation of
mutations with LOH
A targeted mutation screen was conducted on the 86
ovarian cancer cases including high-grade serous and
endometrioid, low-grade endometrioid, clear cell and
mucinous subtypes. Somatic coding mutations were
detected in both candidate (561 variants in 366 genes,
Additional file 2: Table S4) and known cancer genes
(58 TP53 mutations in 56 cases and two mutations in
BRCA1). Eighty-nine genes had two or more non-
synonymous mutations. The classic two-hit hypothesis
would predict that driver genes have homozygous,
deleterious mutations in samples with LOH. With re-
spect to deleterious mutation status this was certainly
true for TP53 and BRCA1 where a high proportion of
somatic mutations were truncating (25/58 and 2/2, re-
spectively) compared to an overall truncating muta-
tion frequency of 13 % (72/561). In addition, among
the 53 cases with TP53 or BRCA1 somatic mutations
where SNP data was available, 50 (94 %) showed
LOH of the wild-type allele. This was is sharp con-
trast with the other candidate genes, where only 181/
520 showed LOH of the wild-type allele (35 %); in
particular, there was no significant difference in LOH
of the wild-type allele between non-synonymous mu-
tations (134/381 with LOH, 35.2 %) and synonymous
mutations (47/139 with LOH, 33.8 %). The overall
frequency of non-synonymous compared to synonym-
ous mutations was 73 % (411/561) for the candidate
TSGs, but 100 % of mutations in known cancer genes
were non-synonymous (60/60). This difference in ratio
suggests that the majority of mutations in candidate
TSGs from LOH regions are likely to be passenger
events, since this rate might be expected without any
strong positive selection [16]. The lack of difference
in LOH between synonymous and non-synonymous
also implies that there is limited selection for homo-
zygosity for the majority of gene mutations.
Significance analysis of recurrently mutated gene
candidates
Within the list of mutated genes, we applied a number
of filters to assess whether any genes could function as
tumor suppressors under either a one-hit or two-hit
mechanism. Firstly, significantly mutated genes were
identified using the MuSiC algorithm [17], which deter-
mines the significance of the observed mutation rate of
each gene based on the background mutation rate in the
sample cohort. Three known ovarian cancer genes (TP53,
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PTEN and CDKN2A) were identified by all three tests
(convolution, likelihood ratio and Fisher’s combined p-
value tests) with a false discovery rate (FDR) of less than
0.10. At this FDR the genes DNAH9, LINGO1, MEF2C,
SAMD11, STARD5, ZNRF4 and ZNF287 were also identi-
fied, although each was supported only by the likelihood
ratio test.
Secondly, the 125 genes with recurrent mutations were
assessed for the proportion of cases with biallelic muta-
tion, including by homozygous deletion from SNP array
data. For genes with mutations in three or more cases,
the proportion of biallelic mutations was greater than
80 % of mutated samples for eight genes (AL355987.1,
CASK, CDKN2A, MAP2K4, NF1, PTEN, RB1 and TP53)
and between 60-80 % for seven genes (FANCA,
GRAMD4, GPR98, IL16, MYOCD, SYNE1 and TEX15).
Biallelic mutations were detected in 2/2 mutated sam-
ples in an additional nine genes (SKG223, APOOL,
BRCA1, CDH8, DACH2, EPHX2, FARP1, PNMA3 and
RAI1).
Finally, genes recurrently targeted by inactivating mu-
tations were identified. Mutations with overtly deleteri-
ous consequences were considered for this analysis,
including nonsense and essential splice site mutations,
frameshift indels and gene deletions. Although missense
amino acid changes and in-frame indels can also nega-
tively impact gene function, interpreting these mutations
in the absence of functional validation is challenging.
Sixteen genes were identified where more than half of
their mutations would be considered clearly deleterious,
including seven known ovarian cancer genes (PTEN,
CDKN2A, MAP2K4, PIK3R1, RB1, FANCA and BRCA1).
These three analyses identified 36 genes as possible
tumour suppressors (Table 1), and it was notable that
seven well characterised tumour suppressors were iden-
tified by at least two of the three methods (BRCA1,
TP53, RB1, PTEN, CDKN2A, FANCA, and MAP2K4), al-
though others were only identified by one method (NF1,
PIK3R1). In contrast, 22 of the 27 (81 %) novel/less well
characterized genes were identified by only 1 method,
indicating that regions of LOH are not strongly enrich-
ing for novel genes with classic tumor suppressor gene
characteristics.
Loss of heterozygosity – what is it good for?
From the data above it appears that we did not identify
dominant, very frequently mutated novel genes where
selection for a classic two-hit tumour suppressor gene
was apparent. So what, if anything, is the LOH for? We
considered five possibilities (Fig. 1) and assessed each in
turn.
1. Classic two-hit hypothesis: high frequency biallelic
genetic inactivation of TSG
2. Epigenetic two-hit hypothesis: biallelic inactivation
through methylation and LOH
3. Multiple alternate gene biallelic inactivation: low
frequency gene disruption
4. Haplo-insufficiency: Single copy gene disruption
5. Modified two-hit hypothesis: reduction to homozy-
gosity of predisposition alleles
1. Classic two-hit hypothesis: high frequency biallelic
genetic inactivation of TSG
This mechanism is demonstrably true for many known
tumour suppressor genes, with TP53 being a clear ex-
ample of a gene functioning as a classical TSG in ovar-
ian cancer [18, 19]. However, from our data and large
published studies such as TCGA, it is clear that novel
genes with a high frequency of biallelic mutations are
exceedingly rare and can not explain the bulk of the ob-
served LOH. For example, 8p undergoes LOH in >40 %
of ovarian carcinomas, but no gene in this region is mu-
tated at frequency higher than 3 % in our or any other
study, although homozygous deletion can target, for ex-
ample, CSMD1 in 11 % of cases [20]. It remains a possi-
bility, however, that genes not represented on our
targeted or exome sequencing platforms could still be
the target of such LOH, for example long non-coding
RNAs.
2. Epigenetic two-hit hypothesis: high frequency
biallelic inactivation through methylation and
LOH
Somatic gene mutation is not the only mechanism of
biallelic inactivation. Some TSGs can be inactivated
through a combination of LOH and promoter hyperme-
thylation, for example MLH1. This methylation can be
acquired somatically or may be a consequence of im-
printing. We assessed this possibility using TCGA ovar-
ian cancer methylation data. Globally, we observed that
there was no enrichment for methylation in regions of
LOH – in samples with LOH at a locus, on average
12.7 % of genes were strongly methylated (probe value
of >0.75), whereas 13.65 % of genes were strongly
methylated when there was no LOH, (Fig. 2a). CNL-
LOH was less likely to have strongly methylated genes
than CNN-LOH (12.3 % vs 12.9 %, p < 0.0001, Chi-
squared test). However, when we analysed the X
chromosome separately, we found that samples with
any LOH were more likely to have low methylation
levels (45.3 % of genes had a probe value of <0.25, com-
pared to 35.5 % in samples without LOH, p < 0.0001
Chi-squared test).
Detection of methylation is challenging from both
technical and biological perspectives. Tumour and cell
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Table 1 Selected mutated genes in candidate TSG screen
Gene Location Description Recessive TSGa Predominant subtypes TCGA mutatedb Detected by
ANKRD32 5q15 ankyrin repeat domain 32 HG S/E + LG E + CC 9 Deleterious
APOOL Xq21.1 apolipoprotein O-like HG S/E 0 Biallelic
BRCA1 17q21.31 breast cancer 1, early onset Y HG S/E 12 Biallelic, Deleterious
C9ORF172 9q34.3 chromosome 9 open reading
frame 172
HG S/E 5 Biallelic
CACNA1B 9q34 calcium channel, voltage-dependent,
N type, alpha 1B subunit
LG E + CC 7 Deleterious
CASK Xp11.4 calcium/calmodulin-dependent
serine protein kinase
HG S/E 2 Biallelic
CDH8 16q22.1 cadherin 8, type 2 HG S/E 9 Biallelic
CDKN2A 9p21 cyclin-dependent kinase
inhibitor 2A
Y Muc 8 MuSiC, Biallelic, Deleterious
CYLC1 Xq21.1 cylicin, basic protein of sperm
head cytoskeleton 1
HG S/E 4 Deleterious
DACH2 Xq21.3 dachshund homolog 2
(Drosophila)
HG S/E 3 Biallelic
DNAH9 17p12 dynein, axonemal, heavy chain 9 LG E 16 MuSiC
EPHX2 8p21 epoxide hydrolase 2, cytoplasmic HG S/E 12 Biallelic
FANCA 16q24.3 Fanconi anemia, complementation
group A
Y HG S/E 12 Biallelic, Deleterious
FARP1 13q32.2 FERM, RhoGEF (ARHGEF) and
pleckstrin domain protein 1
HG S/E 3 Biallelic
GPR98 5q13 G protein-coupled receptor 98 HG S/E 17 Biallelic
GRAMD4 22q13.31 GRAM domain containing 4 HG S/E 18 Biallelic, Deleterious
IL16 15q26.3 interleukin 16 HG S/E 4 Biallelic, Deleterious
LINGO1 15q24.3 leucine rich repeat and Ig
domain containing 1
HG S/E 4 MuSiC
MAP2K4 17p12 mitogen-activated protein
kinase kinase 4
Y HG S/E 12 Biallelic, Deleterious
MEF2C 5q14.3 myocyte enhancer factor 2C HG S/E 8 MuSiC
MYOCD 17p11.2 myocardin HG S/E 7 Biallelic, Deleterious
NF1 17q11.2 neurofibromin 1 Y HG S/E 37 Biallelic
PIK3R1 5q13.1 phosphoinositide-3-kinase,
regulatory subunit 1 (alpha)
Y LG E 6 Deleterious
PNMA3 Xq28 paraneoplastic Ma antigen 3 HG S/E 2 Biallelic
PTEN 10q23 phosphatase and tensin
homolog
Y LG E 25 MuSiC, Biallelic, Deleterious
RAI1 17p11.2 retinoic acid induced 1 HG S/E 4 Biallelic
RB1 13q14.2 retinoblastoma 1 Y HG S/E 32 Biallelic, Deleterious
RPS6KA6 Xq21.1 ribosomal protein S6 kinase,
90 kDa, polypeptide 6
HG S/E + LG E 0 Deleterious
SAMD11 1p36.33 sterile alpha motif domain
containing 11
HG S/E 7 MuSiC, Deleterious
SKG223 8p23.1 Sugen kinase 223 HG S/E + Muc 7 Biallelic
STARD5 15q26 StAR-related lipid transfer
(START) domain containing 5
HG S/E 1 MuSiC
SYNE1 6q25 spectrin repeat containing,
nuclear envelope 1
HG S/E 14 Biallelic
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type heterogeneity may influence the degree of methyla-
tion detected, so we also took an alternative approach
where we used the methylation array data to test
whether there were genes that were more strongly meth-
ylated in samples with LOH compared to samples with-
out LOH. Using a multiple testing correction p-value
threshold of 2.2x10−6, there were 1584/22374 (7 %)
methylation probes that were significantly differentially
methylated. Interestingly, 28 % of these significant
probes were located on the X chromosome and indeed
51 % of all probes on the X chromosome were signifi-
cantly differentially methylated, with lower average levels
of methylation in samples with LOH compared to sam-
ples without LOH. On the autosomes, the outcome was
reversed: 50.3 % of the statistically significant probes had
a fold-change difference in mean methylation of >1.5,
while only 1.1 % had a fold-change difference of <0.75
(Fig. 2b). Thus, for the X chromosome it appears there
is selection for retaining the active copy, perhaps be-
cause loss of this copy would be cell lethal as an effective
homozygous inactivation of the chromosome. In con-
trast, for the autosomes there appears to be selection for
increased methylation by LOH.
We also evaluated whether there was any difference by
the type of LOH. For those genes occurring in a region
of LOH with at least 20 % frequency, we determined
whether a probe was in a CNL-LOH enriched locus
(>66 % of samples with LOH also had CN loss) or a
CNN-LOH enriched locus (>66 % of samples with LOH
were CNN). Of the CNL-enriched probes, 11.3 % were
significantly differentially methylated, compared to
21.7 % of CNN-enriched probes (p < 0.0001, Chi-squared
test, Fig. 2c). This data would support a model whereby
differential methylation is more commonly selected for
in regions of CNN-LOH than CNL-LOH.
3. Multiple alternate gene biallelic inactivation: low
frequency gene disruption
Another possibility is that particular loci harbour mul-
tiple TSGs but individual tumours only require one to
be inactivated and the gene targeted can differ from
tumour to tumour. If this is the case then locating the
TSGs by mapping overlapping regions of LOH would in-
correctly flag the interval between two TSG as the likely
location of the TSG – in effect then the peak LOH re-
gions may not be the most likely places to find the tar-
geted gene(s). To evaluate this possibility, we used
TCGA data to see whether regions of LOH were
enriched for somatic mutations on a sample-by-sample
basis. Cases with both somatic exome and SNP array
data were used (n = 266). There were 13,148 coding
somatic mutations, of which 29.7 % were located within
a region of LOH in the sample where it was observed.
The average overlap of all the genes assayed with regions
of LOH per sample was 35.5 %. Thus, somatic muta-
tions are if anything under-represented in regions of
LOH (Binomial test p < 0.0001). Given that most of
these mutations are likely to be passengers, we evalu-
ated whether this was true for non-synonymous or
overtly deleterious mutations (nonsense, frameshift,
essential splice site). For deleterious mutations, 38.2 %
were in regions of LOH (p = 0.035, Binomial test),
whereas only 25.2 % of the non-synonymous muta-
tions were in regions of LOH, similar to the 22.2 %
observed for synonymous mutations. The signal for
deleterious mutations was substantially reduced if
TP53 was excluded (34.9 % of deleterious and 28.5 %
of other non-synonymous mutations had LOH). Thus,
regions of LOH are slightly enriched for deleterious
mutations, but not for other non-synonymous or si-
lent mutations.
We then evaluated whether there was a difference in
mutation frequency in CNN versus CNL regions of
LOH on a case by case basis as above (Fig. 3). Excluding
TP53, there were fewer mutations in regions of CNL-
LOH than would have been expected based on the over-
all percentage of the exome affected (19.8 % of muta-
tions were in CNL-LOH regions, whereas 26.8 % of the
exome was affected by CNL-LOH, p < 0.0001, Binomial
test). The difference was less striking when considering
overtly deleterious mutations only (24.6 % vs 26.8 %, p =
0.09, Binomial test). For CNN-LOH, the overall differ-
ence was small (8.8 % of mutations vs 8.7 % of the ex-
ome affected by CNN-LOH, p = 0.7, Binomial test),
however there were more deleterious mutations than
Table 1 Selected mutated genes in candidate TSG screen (Continued)
TEX15 8p22 testis expressed 15 HG S/E 13 Biallelic
TP53 17p13.1 tumor protein p53 Y HG S/E 302 MuSiC, Biallelic
ZNF287 17p11.2 zinc finger protein 287 HG S/E 4 MuSiC, Deleterious
ZNRF4 19p13.3 zinc and ring finger 4 HG S/E 1 MuSiC
LG E, low-grade endometrioid; HG S/E, high-grade serous/endometrioid; Muc, mucinous; CC, clear cell
aKnown recessive tumour suppressor gene according to the Cancer Gene Census [32]
bNumber of high-grade serous TCGA samples with somatic point mutations and indels including large homozygous deletions. Mutation data for 316 TCGA
samples [33] was accessed through the cBio Cancer Genomic Portal [34]
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expected (10.3 % vs 8.7 %, p = 0.05, Binomial test). When
TP53 was included, both total mutations (9.2 %) and
deleterious mutations (11.4 %) in CNN-LOH regions
were increased. Silent mutations were the most likely to be
underrepresented in CNL-LOH regions (17.2 % vs 26.8 %).
It is possible, therefore, that mutations are seen less often
in CNL-LOH regions simply as a consequence of decreased
DNA dosage. The enrichment of deleterious mutations in
CNN-LOH regions, however, suggests the presence of
positive selection for mutations in TSGs.
Fig. 1 Models of LOH. Boxes = genes; “X” = inactivating mutation; A, B = alternative alleles of a single nucleotide polymorphism. In the top panels,
the black line on the graph represents the overall frequency of LOH observed in tumour samples across the chromosome, while the red bars are
the frequency of mutation in a particular gene. Thus, for the classic two-hit model, the frequency of mutation is similar to the frequency of LOH,
while in the low frequency model, the frequency of LOH is higher than the mutation rate, because each sample is mutated in a different gene. In
the bar graphs below, at left, the red bars represent the frequency of the A allele that is retained in samples with LOH at the locus; thus, the risk
locus (*) has a higher proportion of the risk allele (A) retained after LOH compared to a non-risk locus, where the A and B alleles are equally
retained. At right, the graphs represents the average reduction in expression of a gene in samples with LOH, compared to samples without LOH;
genes in LOH regions show a reduction in expression
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4. Haplo-insufficiency: Single copy gene disruption
We and others have shown that loss of a single gene
copy can reduce gene expression [6, 21]. A recent study
showed that regions of copy number loss are enriched
for tumour-suppressor genes [22], but that each gene
might have a limited effect on its own. Chromosome
complementation studies, where all or part of a
chromosome is introduced into cell lines with LOH of
that chromosome via microcell-mediated monochro-
mosome transfer, have frequently been able to show re-
duction in tumorigenicity of the cell line thus
complemented [23, 24], but have only rarely been able
to implicate a single gene responsible [25, 26]. Thus,
haplo-insufficiency of multiple genes, each with a small
effect, could contribute to the non-random pattern of
LOH observed in ovarian cancer, especially for chromo-
somal regions that are weighted towards CNL-LOH
such as 8p and X, rather than CNN-LOH, such as 17.
We previously observed a correlation between the per-
centage of genes under-expressed and the percentage of
cases with CNL-LOH, as opposed to CNN-LOH, in a
region-wise comparison of LOH vs. no LOH [6]. In an
analysis of TCGA data, we compared the expression of






































































































Fig. 2 Methylation. a Frequency of probes on the HM27 methylation
array that have high (value > 0.75), intermediate (0.25-0.75) and low
(<0.25) methylation associated with LOH in a sample, comparing all
autosomes (no difference between LOH and no LOH) and
chromosome X (more low methylation probes in LOH regions). b
Considering only probes that were significantly different between LOH
and no LOH, the frequency of significant probes where the mean
methylation ratio (LOH/no LOH) was increased (>1.5, higher in LOH) or
decreased (<0.75, higher in no LOH). c Percentage of significant
methylation probes that are located in regions where the majority (>2/3)
of LOH is either copy number loss, neutral or neither. Only regions with
at least 20 % LOH were included















Fig. 3 Mutation load. Frequency of mutations of various types in
copy number neutral and copy number loss regions, compared to
the overall frequency of LOH across the exome (“LOH overall”).
Deleterious mutations are enriched in CNN-LOH; all other mutations
types are less frequent in copy number loss regions
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10,925 genes between cases with and without LOH.
3,780 genes (34.6 %) were significantly differentially
expressed (at a multiple testing p-value threshold of
4.56x10−6), and all significant genes were under-
expressed in samples with LOH compared to samples
without LOH. When comparing CNN-LOH to CNL-LOH
in genes with at least 20 % frequency of LOH, only 1/163
genes (0.6 %) at CNN-LOH enriched loci were significantly
differentially expressed, compared to 2701/5740 (47 %)
CNL-LOH enriched genes (p < 0.0001, Chi-squared test,
Fig. 4). This result supports the idea that chromosomal re-
gions with CNL-LOH may contain genes where loss of a
single copy results in reduced gene expression and a select-
ive advantage to the cell. In contrast, chromosomal regions
with little copy number loss may contain essential genes for
which haplo-insufficiency is cell lethal.
5. Modified two-hit hypothesis: reduction to homo-
zygosity of predisposition alleles
In familial cancer predisposition syndromes, it is com-
mon for the remaining wild-type allele to be lost by
LOH, for example BRCA1 pathogenic variants are usu-
ally reduced to homozygosity in breast and ovarian car-
cinomas [3, 27]. However, common low-penetrance risk
alleles could also be targeted by LOH leading to an en-
hancement of their cancer-promoting role. We assessed
this using nine SNP loci identified in the iCOGs study
[28, 29] as predisposing to all ovarian cancer types or
high-grade serous ovarian cancer. Two of these SNPs
were present on the Affymetrix SNP 6.0 array, the re-
mainder were represented by SNPs in linkage disequilib-
rium (r2 > 0.7, from HapMap [30]). Where possible, up
to four linked SNPs were evaluated.
For each SNP, we assessed whether cases were hetero-
zygous in their normal DNA, and what proportion of
these with LOH of the region were homozygous for the
risk allele in the tumour DNA using TCGA and our own
data (n = 364). Interestingly, two SNPs at 10p12 linked
to the risk allele rs1232180 were found to be signifi-
cantly more likely to have lost the non-risk allele than
the risk allele (Table 2). Some other SNPs linked to a risk
allele also showed significantly non-random loss of the
non-risk allele, but the data were not consistent across all
SNPs examined at the locus (e.g. 17q21, 3q25 and 9p22). It
is not clear whether these discrepancies could be due to
technical variation in the SNP calling; alternative methods
may be required to assess this possibility. The remainder of
SNPs were not significant, however several are uncommon,
limiting the power of the analysis. Thus, it is possible that
some LOH may be selected for through the phenotypic ef-
fect of reduction to homozygosity of predisposition alleles.
Conclusion
The broader relevance of LOH in cancer has been de-
bated for some time [5, 31] although many of the
criticisms stemmed from technical issues that are be-
ing overcome by newer methodologies. Our initial as-
sumption for this study was that we would detect
high-frequency mutated genes in the minimal peak
regions of LOH we had defined by LOH mapping
using these newer methodologies; i.e. a classic two-hit
model. However, the biology of LOH does not sup-
port this assumption and with large-scale tumour
studies it is now possible to explore the many possi-
bilities for the functional significance of this genetic
event as summarised in Table 3. We suggest that the
non-random patterns of LOH detected in cancer are
a result of multiple different mechanisms operating to
affect multiple genes, which may differ from tumour
to tumour yet collectively play a role in the develop-
ment of the tumorigenic phenotype. It is worth not-
ing the differences in CNL-LOH versus CNN- LOH,
with the latter appearing more relevant for selection
of deleterious mutations and methylation, in contrast
to global changes in gene expression. Identifying the
specific driver genes targeted in a particular cancer
remains a challenge given the multiple possible rea-
sons for selection of an LOH event.
Fig. 4 Expression. The percentage of significantly differentially
expressed genes in regions where the majority (>2/3) of LOH is
either copy number loss, neutral or neither. Only regions with at
least 20 % LOH were included
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Table 3 Summary of LOH – what is it good for?
Hypothesis Mechanism Plausibility Frequency Impact LOH type
Classic two-hit hypothesis High frequency biallelic genetic inactivation of TSG
via mutation and LOH or homozygous deletion
Strong Rare High More CNN-LOH
Modified two-hit hypothesis Reduction to homozygosity of predisposition
alleles
Low Rare Low Unknown
Epigenetic two-hit hypothesis Biallelic inactivation through methylation and LOH Moderate Unknown Moderate More CNN-LOH
Haplo-insufficiency Single copy gene disruption through copy number
loss
Strong Common Moderate CNL-LOH
Multi-gene biallelic inactivation Low frequency gene disruption through all of the
above mechanisms
Strong Common Unknown Either
Table 2 Ovarian cancer GWAS SNPs and LOH
SNPa Risk Alleleb Locus hetc hom AA BB NC N CHI sq Direction % LOHd N LOH Affy SNP Rsquared
rs1243180 NA 10p12
rs1243188 minor/A 10p12 112 183 22 6 41 364 0.0025 yes 0.20 28 SNP_A-2024177 0.881
rs7098100 minor/B 10p12 132 181 1 9 41 364 0.0114 yes 0.07 10 SNP_A-8636193 0.781
rs757210 NA 17q12
rs11658063 minor/B 17q12 23 148 44 44 105 364 1.0000 . 0.79 88 SNP_A-8714923 0.704
rs9303542 NA 17q21
rs4451990 minor/B 17q21 20 197 49 61 37 364 0.2526 . 0.85 110 SNP_A-2282117 1
rs12944592 minor/B 17q21 24 198 54 60 28 364 0.5741 . 0.83 114 SNP_A-1836563 1
rs12452212 minor/A 17q21 19 196 74 53 22 364 0.0624 yes 0.87 127 SNP_A-2128564 1
rs9894812 minor/A 17q21 20 198 70 48 28 364 0.0428 yes 0.86 118 SNP_A-2209606 1
rs8170 NA 19p13
rs34084277 minor/B 19p13 80 260 9 8 7 364 0.8084 . 0.18 17 SNP_A-1788674 1
rs2072590 NA 2q31
rs711830 minor/B 2q31 77 160 8 14 105 364 0.2008 . 0.22 22 SNP_A-8652216 0.965
rs7651446 NA 3q25
rs344008 minor/A 3q25 58 297 2 3 4 364 0.6547 . 0.08 5 SNP_A-8543714 0.85
rs2292336 minor/B 3q25 48 299 2 5 10 364 0.2568 . 0.13 7 SNP_A-8587822 0.85
rs17380639 minor/A 3q25 28 320 11 3 2 364 0.0325 yes 0.33 14 SNP_A-2078455 0.85
rs11782652 minor/B 8q21 38 291 8 7 20 364 0.7963 . 0.28 15 SNP_A-8702651 .
rs10088218 major/A 8q24 47 280 11 11 15 364 1.0000 . 0.32 22 SNP_A-1801410 .
rs1516974 major/A 8q24 45 291 4 15 9 364 0.0116 no 0.30 19 SNP_A-2088878 1
rs3814113 NA 9p22
rs7032221 major/B 9p22 123 201 6 11 23 364 0.2253 yes 0.12 17 SNP_A-8603886 1
rs10738467 major/B 9p22 111 206 5 11 31 364 0.1336 yes 0.13 16 SNP_A-8328297 0.892
rs10962668 major/B 9p22 103 177 7 22 55 364 0.0053 yes 0.22 29 SNP_A-4198891 0.794
a SNPs in bold are those named in the GWAS iCOG publication [29] All others are linked as indicated by the R-squared value of >0.7. If the minor allele is the risk
allele named, it is assumed that this will also be the case for the linked SNP
b Minor = risk allele is the less frequent allele in the population. A, B = risk allele corresponds to the “A” or “B” allele respectively in the Affymetrix array
nomenclature. NA = not on Affymetrix SNP6 array
c Het = Number of cases where germline and tumour are heterozygous, hom = cases where germline is heterozygous, AA, BB = germline is heterozygous, tumour
is homozygous for A or B respectively, NC = no call in either tumour or germline. N = total number
d % LOH is the number of individuals with loss of one allele divided by the total number of heterozygous individuals as measured at that SNP, i.e. not the overall
% of LOH that could be determined from all cases using a wider genetic window. This may therefore include regions of extreme allelic imbalance (e.g. likely
for 8q24)
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